Novo Nordisk A/S (NYSE:NVO) Trading 1.6% Higher - Still a Buy?

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s share price shot up 1.6% during trading on Tuesday . The company traded as high as $70.60 and last traded at $70.43. 2,537,071 shares were traded during mid-day trading, a decline of 65% from the average session volume of 7,245,082 shares. The stock had previously closed at $69.32.

Wall Street Analysts Forecast Growth

A number of research firms have commented on NVO. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. Finally, Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Trading Up 0.2%

The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The firm's 50-day simple moving average is $70.19 and its 200 day simple moving average is $75.37. The stock has a market capitalization of $311.66 billion, a P/E ratio of 20.65, a PEG ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strategic Investment Solutions Inc. IL increased its holdings in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $27,000. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. Finally, Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.